Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Cancer Immunology, Immunotherapy : CII|December 23, 2004
Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosisAlan D Brooks, Thomas J SayersPlos One|August 12, 2014
Increased secretory leukocyte protease inhibitor (SLPI) production by highly metastatic mouse breast cancer cellsKevin T Sayers, Alan D Brooks, Thomas J Sayers, et al.Molecular Cancer Research : MCR|May 6, 2010
Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complexAlan D Brooks, Kristen M Jacobsen, Wenqing Li, et al.Annals of the New York Academy of Sciences|December 31, 2005
The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosisAlan D Brooks, Teresa Ramirez, Uhi Toh, et al.Cancer Research|August 6, 2009
Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicityAnil Shanker, Alan D Brooks, Kristen M Jacobsen, et al.Journal of Medicinal Chemistry|March 4, 2017
17β-Hydroxywithanolides as Sensitizers of Renal Carcinoma Cells to Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) Mediated Apoptosis: Structure-Activity RelationshipsYa-Ming Xu, Alan D Brooks, E M Kithsiri Wijeratne, et al.Cancer Research|January 9, 2003
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancerNaoko Seki, Yoshihiro Hayakawa, Alan D Brooks, et al.Cancer Immunology, Immunotherapy : CII|December 18, 2008
A cell-based high-throughput screen to identify synergistic TRAIL sensitizersNancy Lynn Booth, Thomas J Sayers, Alan D Brooks, et al.Apoptosis : an International Journal on Programmed Cell Death|September 20, 2011
Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosisCurtis J Henrich, Cheryl L Thomas, Alan D Brooks, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2002
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforinNaoko Seki, Alan D Brooks, Clive R D Carter, et al.Pageof 2